LBL-024 not checked

Nanjing Leads Biolabs Co.,Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
11 active
11 in total
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Advanced Solid Tumour (4 trials), Advanced Extrapulmonary Neuroendocrine Carcinoma, Advanced Neuroendocrine Carcinoma, Advanced Solid Tumor, Advanced Melanoma, Ovarian Cancer, Triple Negative Breast Cancer, Metastatic Colorectal Carcinoma
Main trialPhase 3
“This trial is a randomized, double-blind, placebo-controlled multicenter phase III clinical study aiming to evaluate the efficacy and safety of LBL-024 compared with placebo in combination with etoposide and cisplatin or carboplatin (EP or EC) for the first-line treatment of advanced EP-NEC patients.”In the company’s words, NCT07720193 on ClinicalTrials.gov

Other drugs for Advanced Solid Tumour

All 2440 drugs for Advanced Solid Tumour

Coming up11

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting 22 Dec 2030 A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
Phase 2Recruiting 24 Dec 2026 A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]
Phase 2Recruiting 26 Dec 2027 A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]
Phase 2Recruiting 30 May 2028 A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
Phase 2Recruiting 26 Dec 2028 A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Phase 1/2Recruiting 28 Dec 2026 A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
Phase 1/2Recruiting Dec 2026 A Phase I/II Clinical Study of LBL-024 in Patients With Advanced Malignant Tumors
Phase 1/2Recruiting 30 Oct 2027 A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.
Phase 1/2Recruiting 25 Dec 2027 A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer
Phase 1/2Recruiting 31 Dec 2027 A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
Phase 1/2Recruiting 4 Sep 2030 A Clinical Trial of LBL-024 Combination Drug in Patients With Metastatic Colorectal Carcinoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LBL-024

Following is part of Solo: you see every change to LBL-024 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in